Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions

• DOI: 10.1186/s12866-020-02070-5
• Publication Date: 2021-01-05T08:03:31Z
• Authors: Elizabeth Gyamfi; Charles A Narh; Charles Quaye; Adiza Abbass; Bartholomew Dzudzor; Lydia Mosi
• Keywords: Mycobacterium ulcerans; Buruli ulcer; Amikacin

Buruli ulcer (BU) is a skin disease caused by Mycobacterium ulcerans and the second most common mycobacterial after tuberculosis in Ghana Côte d'Ivoire. M. produces mycolactone, an immunosuppressant macrolide toxin, responsible for characteristic painless nature of infection. Secondary infection ulcers before, during treatment has been associated with delayed wound healing resistance to streptomycin rifampicin. However, not much known bacteria causing these infections as well antimicrobial drugs treating secondary microorganism. This study sought identify microbial BU lesions determine their levels antibiotic due prolonged therapy required ulcer.Swabs from fifty-one suspected cases were sampled Amansie Central District St. Peters Hospital (Jacobu) through active case surveillance. Forty samples positive. identified all (N = 51). The predominant both Non-BU groups Staphylococci spp Bacilli spp. diverse detected among patients who yet on treatment. Fungal species Candida spp, Penicillium Trichodema Selected isolates susceptible clarithromycin amikacin patients. Majority, however, had high streptomycin.Microorganisms other than colonize proliferate lesions. microorganisms wounds mainly Staphylococcus Bacillus Pseudomonas These less under compared those without delay that are experienced some could be result fungi colonizing proliferating Clarithromycin likely suitable clearance ulcer.